895519-97-8 Usage
General Description
4-(4-ethylpiperazin-1-ylmethyl)benzoic acid is a chemical compound that belongs to the class of benzoic acids. It contains a piperazine ring and an ethyl group attached to the nitrogen atom of the piperazine ring. 4-(4-ETHYLPIPERAZIN-1-YLMETHYL)BENZOIC ACID is often used in pharmaceutical research as a building block for the synthesis of potential drug candidates. It has been studied for its potential therapeutic applications in various medical conditions, and its structure makes it a valuable precursor in the development of novel pharmaceuticals. Additionally, it may have potential applications in the field of chemical biology and medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 895519-97-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,9,5,5,1 and 9 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 895519-97:
(8*8)+(7*9)+(6*5)+(5*5)+(4*1)+(3*9)+(2*9)+(1*7)=238
238 % 10 = 8
So 895519-97-8 is a valid CAS Registry Number.
InChI:InChI=1/C14H20N2O2/c1-2-15-7-9-16(10-8-15)11-12-3-5-13(6-4-12)14(17)18/h3-6H,2,7-11H2,1H3,(H,17,18)
895519-97-8Relevant articles and documents
Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy
Premnath, Padmavathy Nandha,Craig, Sandra N.,Liu, Shu,McInnes, Campbell
, p. 3754 - 3760 (2016)
Inhibition of cyclin dependent kinase 2 (CDK2) in complex with cyclin A in G1/S phase of the cell cycle has been shown to promote selective apoptosis of cancer cells through the E2F1 pathway. An alternative approach to catalytic inhibition is to target the substrate recruitment site also known as the cyclin binding groove (CBG) to generate selective non-ATP competitive inhibitors. The REPLACE strategy has been applied to identify fragment alternatives and substituted benzoic acid derivatives were evaluated as a promising scaffold to present appropriate functionality to mimic key peptide determinants. Fragment Ligated Inhibitory Peptides (FLIPs) are described which potently inhibit both CDK2/cyclin A and CDK4/cyclin D1 and have preliminary anti-tumor activity. A structural rationale for binding was obtained through molecular modeling further demonstrating their potential for further development as next generation non ATP competitive CDK inhibitors.
